As depicted above, it becomes also clear that combined approaches, like the inhibition of the EGFR/BRAF-axis in BRAF V600E mutated colorectal cancers [64], could be used to overcome primary resistance in histological subtypes. Here, EGFR is linked to colorectal cancer.